Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atherosclerotic plaque burden reduction in Native and Intervened coronary arteries as well as in other Major arteries by High Dose ATorvastatin ThErapy-A double blind, randomized study (ANIMATE)

Next Previous
Trial Profile

Atherosclerotic plaque burden reduction in Native and Intervened coronary arteries as well as in other Major arteries by High Dose ATorvastatin ThErapy-A double blind, randomized study (ANIMATE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Atherosclerosis; Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms ANIMATE

Most Recent Events

  • 16 Apr 2012 New source identifed and integrated (Chinese Clinical Trials Register record ChiCTR-TRC09000649).
  • 05 Nov 2010 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top